GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-4.37%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$447M
AUM Growth
+$447M
(-7.6%)
Cap. Flow
-$6.87M
Cap. Flow
% of AUM
-1.54%
Top 10 Holdings %
Top 10 Hldgs %
59.14%
Holding
40
New
10
Increased
10
Reduced
5
Closed
10
Top Buys
| 1 |
Amicus Therapeutics
FOLD
|
$15.4M |
| 2 |
Dyne Therapeutics
DYN
|
$14.2M |
| 3 |
Repare Therapeutics
RPTX
|
$13.6M |
| 4 |
Dianthus Therapeutics
DNTH
|
$10.9M |
| 5 |
Kura Oncology
KURA
|
$10.4M |
Top Sells
| 1 |
Iovance Biotherapeutics
IOVA
|
$29.4M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$20.4M |
| 3 |
Biogen
BIIB
|
$14.7M |
| 4 |
Lantheus
LNTH
|
$13.9M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$11.2M |
Sector Composition
| 1 | Healthcare | 97.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MacroGenics
MGNX
$112M
| $37M | 7.77% | 1,378,495 +28,495 | +2% | +$765K |
|
2
Rocket Pharmaceuticals
RCKT
$354M
| $36.2M | 7.59% | 817,040 +57,040 | +8% | +$2.53M |
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $34.5M | 7.23% | 505,670 +129,800 | +35% | +$8.85M |
|
4
United Therapeutics
UTHR
$13.8B
| $31.6M | 6.64% | 176,406 +20,000 | +13% | +$3.59M |
|
5
Insulet
PODD
$23.9B
| $28.7M | 6.02% | 104,600 +15,000 | +17% | +$4.12M |
|
6
Exelixis
EXEL
$10.1B
| $25.4M | 5.33% | 1,394,107 +193,007 | +16% | +$3.52M |
|
7
Collegium Pharmaceutical
COLL
$1.22B
| $20.4M | 4.27% | 861,410 | – | – |
|
|
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
| $18.7M | 3.92% | 4,830,000 +75,000 | +2% | +$290K |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $16.2M | 3.39% | 100,000 -35,000 | -26% | -$5.65M |
|
10
Travere Therapeutics
TVTX
$1.56B
| $15.8M | 3.32% | 1,084,300 +490,588 | +83% | +$7.16M |
|
|
11
Amicus Therapeutics
FOLD
$2.34B
| $15.4M | 3.24% | +1,600,000 | New | +$15.4M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $14.2M | 2.98% | 250,000 -132,085 | -35% | -$7.5M |
|
|
13
Dyne Therapeutics
DYN
$1.92B
| $14.2M | 2.97% | +672,559 | New | +$14.2M |
|
|
14
Repare Therapeutics
RPTX
$71.7M
| $13.6M | 2.85% | +436,089 | New | +$13.6M |
|
15
Ocular Therapeutix
OCUL
$2.12B
| $13M | 2.74% | 919,887 -87,125 | -9% | -$1.24M |
|
|
XENT
16
DELISTED
Intersect ENT, Inc
XENT
| $12M | 2.51% | 700,000 -632,773 | -47% | -$10.8M |
|
17
Puma Biotechnology
PBYI
$254M
| $11.9M | 2.5% | 1,300,000 | – | – |
|
|
18
Biogen
BIIB
$19.4B
| $11.3M | 2.36% | 32,500 -42,500 | -57% | -$14.7M |
|
|
19
Dianthus Therapeutics
DNTH
$759M
| $10.9M | 2.28% | +1,111,111 | New | +$10.9M |
|
|
20
Kura Oncology
KURA
$686M
| $10.4M | 2.19% | +500,000 | New | +$10.4M |
|
21
AnaptysBio
ANAB
$569M
| $10.4M | 2.18% | +400,051 | New | +$10.4M |
|
22
Olema Pharmaceuticals
OLMA
$375M
| $9.21M | 1.93% | +329,086 | New | +$9.21M |
|
|
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
| $8.53M | 1.79% | 1,974,000 +1,624,400 | +465% | +$7.02M |
|
24
InflaRx
IFRX
$108M
| $6.53M | 1.37% | 2,200,000 | – | – |
|
25
Rigel Pharmaceuticals
RIGL
$697M
| $6.51M | 1.37% | +1,500,000 | New | +$6.51M |
|